CX-1796

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameCX-1796
Drug Alias Namelow impact AMPAKINE compound (Cortex pharmaceuticals)CX-1796
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate receptor ionotropic AMPA agonists
TargetsGlutamate receptor ionotropic AMPA
Therapy Area/IndicationsAttention Deficit Disorder with HyperactivityAlzheimer DiseaseRespiratory Tract Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRespirerx Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRespirerx Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsAttention Deficit Disorder with HyperactivityAlzheimer DiseaseRespiratory Tract Diseases

Other Information

ATC CodeN/A
Related LinksN/A